Theophylline low-dose inhalation - Pulmagen Therapeutics

Drug Profile

Theophylline low-dose inhalation - Pulmagen Therapeutics

Alternative Names: ADC 4022; Theophylline Solution for Inhalation - Pulmagen

Latest Information Update: 19 Aug 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Argenta Discovery
  • Developer Argenta; Pulmagen Therapeutics
  • Class Antiasthmatics; Antibronchitics; Bronchodilators; Xanthines
  • Mechanism of Action Histone deacetylase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 31 Mar 2014 Argenta has been acquired by Charles River Laboratories
  • 02 Feb 2010 Argenta Discovery has been acquired by Galapagos NV
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top